When glacial ice sheets melt, something counterintuitive happens to sea levels. Logic might suggest that nearby levels would rise, but instead they fall. Thousands of miles away, however, they do go up in a kind […]
The school will be renamed after one of the university’s former presidents and an alumnus who was an accomplished clarinetist — both of whom grew up together in Rhode Island. Click here to view original […]
LOWELL, Mass. & WESTON, Fla.–(BUSINESS WIRE)–Dave Shaw, senior managing director and global HR transformation/delivery lead at Accenture, has joined The Workforce Institute at UKG advisory board. Click here to view original post
CAMBRIDGE, Mass.–(BUSINESS WIRE)–The Engine, built by MIT, today announced the opening of The Engine at 750 Main, its new headquarters in Cambridge. The Engine invests in Tough Tech—transformative technology that solves the world’s most important […]
Positive data on the Cambridge company’s Alzheimer’s drug released late Tuesday restored some investor and analyst confidence. But patient advocates are holding out for full study results. Click here to view original post
While not a magic bullet, the modest effectiveness of lecanemab reported by Eisai/Biogen would give physicians one part of the treatment puzzle—combination therapies remain the holy grail NEW YORK, Sept. 28, 2022 /PRNewswire/ — The […]
The announcement Tuesday night from Eisai and Biogen that their experimental medicine, lecanemab, reduced Alzheimer’s patients’ decline as measured by a clinical questionnaire is one of the biggest — and potentially happiest — shocks in […]
CHICAGO, Sept. 27, 2022 /PRNewswire/ — On behalf of the more than 6 million Americans living with Alzheimer’s disease and their families, the Alzheimer’s Association enthusiastically welcomes the positive topline data reported today by Eisai […]
The Translational Institute for Molecular Therapeutics was formed in February and was the first team to deliver a human gene therapy for Tay-Sachs, and is now working with families on five other diseases, including one […]
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Sept. 27, 2022 /PRNewswire/ — Harbour BioMed (“HBM”, HKEX: 02142) today announces that it has completed the first subject dosing in a phase I study of HBM9378 (or […]
© 2022 Biotech Networks, LLC
